Mesoblast (ASX:MSB) said that the pricing information for its US Food and Drug Administration (FDA) approved inflammatory disease treatment, Ryoncil, is now listed in all four major US drug pricing compendia, according to a Friday filing with the Australian bourse.
Ryoncil is the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease, a life-threatening condition with high mortality rates.
The listings provide healthcare providers with National Drug Codes (NDC), manufacturing details, and uniform pricing for treatment kits, the filing said.
Treatment centers can now order kits specific to patient weight with consistent pricing across all categories, the filing added.
The pricing compendia include Merative Micromedex RED BOOK, First Databank FDB MedKnowledge, Elsevier Gold Standard Drug Database, and Wolters Kluwer Medi-Span Price Rx.
Shares of the company rose 2% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.